Articles
| Open Access |
DOI: Characteristic Of The Morphometric Parameters Of The Liver In Polypragmasia
Usanov Sanat Sadinovich , Assistant Of The Department Of Anatomy And Clinical Anatomy, Samarkand State Medical Institute, Samarkand, UzbekistanAbstract
We have studied the morphological, morphometric parameters of the liver of white rats. Against the background of polypharmacy, when using non-steroidal anti-inflammatory drugs, it was revealed in the structure of the liver, which led to various damage to the liver parenchyma. The simultaneous use of non-steroidal anti-inflammatory drugs leads to acute or chronic liver failure in rats. The longer the therapy for chronic diseases, the more pronounced morphological changes (necrosis, fibrosis, and cholestasis).
Keywords
Liver, Polypharmacy, Non-Steroidal Therapy, Morphology, Morphomrytic Changes
References
Baykova I.E., Nikitin I.G. (2009) Medicinal liver damage. RMJ (Russian Medical Journal), 1. pp. 4-10.
Bueverov A.O. (2009) Possibilities of treating drug-induced liver damage in conditions of the need to continue taking hepatotoxic drugs. Treat. physician, 2. Pp. 3-8.
Zvyagintseva T.D., Chernobay A.I. (2011) Medicinal hepatitis: from pathogenesis to treatment. Medicine and Pharmacy News, 375. pp. 23-28.
Zvyagintseva T.D., Chernobay A.I. (2011) Basic principles of treatment of chronic viral hepatitis. In the book: Chronic liver disease. Odessa, pp. 109-153
Zvyagintseva T.D., Chernobay A.I. (2006) Alcohol-viral liver damage: the effectiveness of the new complex hepatoprotector "PM Sirin". Semeina medicine, 2. Pp. 44–48.
Klyuchareva A.A. (2007) Medicinal hepatitis. Medical News, 14. Pp. 19-24.
Morozov Yu.A., Kucheryavyy Yu.A. (2011) Hepatoprotectors in clinical practice: rational aspects of use. A guide for doctors. 4TE Art., Moscow, p. 28.
Polunina T.E. (2013) Management of patients with drug-induced liver damage. Difficult Patient, 4. Pp. 8-13.
Kharchenko N.V., Anokhina G.A., Kharchenko V.V. (2013) Complex multifunctional hepatoprotectors in the treatment of patients with non-alcoholic liver disease in combination with hypertension. Practicing Likar, 1. Pp. 64-66.
Shirokova E.N. (2012) Medicinal lesions of the liver. Lecture at the All-Russian Internet Congress of Specialists in Internal Medicine. (internist.ruhttp: //www.internist.ru/articles/vnutrennie/vnutrennie_671.html).
Shuba N.M., Voronova T.D. (2009) NSAID hepatotoxicity: is there a real threat? Ukr. rheumatol. zhurn., 1 (35). Pp. 33–39.
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., ... & Daly, A. K. (2011). Case definition and phenotype standardization in drug‐induced liver injury. Clinical Pharmacology & Therapeutics, 89(6), 806-815.
Banks A., Zimmerman H., Isshak K., Harter J.G. (1995) Diclofenak-associated hepatotoxicity: an analysis of 180 cases report to the Food and Drug Administration as adverse reactions. Hepatology. 22 (3). Pp. 820-870.
Bell, L. N., & Chalasani, N. (2009, November). Epidemiology of idiosyncratic drug-induced liver injury. In Seminars in liver disease (Vol. 29, No. 04, pp. 337-347). © Thieme Medical Publishers.
Bhogaraju, A., Nazeer, S., Al-Baghdadi, Y., Rahman, M., Wrestler, F., & Patel, N. (1999). Diclofenac-associated hepatitis. Southern medical journal, 92(7), 711-713.
Leitner, J. M., Graninger, W., & Thalhammer, F. (2010). Hepatotoxicity of antibacterials: pathomechanisms and clinical data. Infection, 38(1), 3-11.
Galati, G., Tafazoli, S., Sabzevari, O., Chan, T. S., & O'Brien, P. J. (2002). Idiosyncratic NSAID drug induced oxidative stress. Chemico-biological interactions, 142(1-2), 25-41.
Hughes, B. (2008). Industry concern over EU hepatotoxicity guidance. Nature Reviews Drug Discovery, 7(9), 719.
Leitner J. M., Graninger W., Thalhammer Infection., 38 (1). pp. 3-11.
Marschall H. U., Wagner M., Zollner G., Trauner M. (2007) Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol. pharm. 4 (6): 895-910.
Article Statistics
Copyright License
Copyright (c) 2021 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.